http://rdf.ncbi.nlm.nih.gov/pubchem/reference/15314750

Outgoing Links

Predicate Object
contentType Case Reports|Journal Article|Research Support, Non-U.S. Gov't
endingPage 274
issn 1470-2045
issueIdentifier 3
pageRange 273-274
publicationName The Lancet. Oncology
startingPage 273
bibliographicCitation Soverini S, Martinelli G, Colarossi S, Gnani A, Rondoni M, Castagnetti F, Paolini S, Rosti G, Baccarani M. Second-line treatment with dasatinib in patients resistant to imatinib can select novel inhibitor-specific BCR-ABL mutants in Ph+ ALL. Lancet Oncol. 2007 Mar;8(3):273–4. doi: 10.1016/s1470-2045(07)70078-5. PMID: 17329198.
creator http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_e8cdb97e62ae0f16995c6784026efd22
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_8875cd4edf75431114f338565484743d
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_8bb4277f61d43572760272c5221557be
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_a1ab571d37b7c622b0ef3c103e948d58
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_54bcb2d44d7c731d0586592cf1c13bd5
http://rdf.ncbi.nlm.nih.gov/pubchem/author/ORCID_0000-0002-4508-0353
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_690a0634fdf80b94ec860ac9db2879d2
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_c647a7e280058ef2478ed4306089a74a
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_d9ad4d6308f921bc94c25782c796d644
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_db6666491972ff8d61642ddf33611347
date 200703
identifier https://doi.org/10.1016/s1470-2045%2807%2970078-5
https://pubmed.ncbi.nlm.nih.gov/17329198
isPartOf https://portal.issn.org/resource/ISSN/1470-2045
http://rdf.ncbi.nlm.nih.gov/pubchem/journal/27004
language English
source https://www.crossref.org/
https://pubmed.ncbi.nlm.nih.gov/
title Second-line treatment with dasatinib in patients resistant to imatinib can select novel inhibitor-specific BCR-ABL mutants in Ph+ ALL
discusses http://id.nlm.nih.gov/mesh/M0470497
http://id.nlm.nih.gov/mesh/M0391958
http://id.nlm.nih.gov/mesh/M0018260
http://id.nlm.nih.gov/mesh/M0457532
http://id.nlm.nih.gov/mesh/M0021333
http://id.nlm.nih.gov/mesh/M0002327
http://id.nlm.nih.gov/mesh/M0016884
hasPrimarySubjectTerm http://id.nlm.nih.gov/mesh/D013844Q000627
http://id.nlm.nih.gov/mesh/D047428Q000627
http://id.nlm.nih.gov/mesh/D011743Q000627
http://id.nlm.nih.gov/mesh/D015464Q000188
http://id.nlm.nih.gov/mesh/D016313Q000235
http://id.nlm.nih.gov/mesh/D015464Q000235
hasSubjectTerm http://id.nlm.nih.gov/mesh/D001549
http://id.nlm.nih.gov/mesh/D000293
http://id.nlm.nih.gov/mesh/D006801
http://id.nlm.nih.gov/mesh/D000068877
http://id.nlm.nih.gov/mesh/D010879Q000627
http://id.nlm.nih.gov/mesh/D000368
http://id.nlm.nih.gov/mesh/D019008
http://id.nlm.nih.gov/mesh/D000069439
discussesAsDerivedByTextMining http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID5291
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID3062316

Incoming Links

Predicate Subject
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID128433595
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID129879136

Total number of triples: 52.